Prospective Registry of Vertigo Due to Vertebrobasilar Transient Attacks.
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Sao Paulo General Hospital
About this trial
Vertigo and dizziness are common neurological complaints in the emergency department and may represent a wide spectrum of etiologies, including vertebrobasilar transient neurological attacks (VB-TNAs). Distinguishing VB-TNAs, particularly vertebrobasilar transient ischemic attacks (VB-TIAs), from migraine-like and other non-vascular conditions is often challenging at first presentation due to the absence of specific biomarkers and overlapping clinical features. The UTRAVERA study is a multicenter, prospective, observational investigation designed to characterize the clinical features of patients presenting with acute transient vertigo or dizziness suspected to be VB-TNAs. The study will also evaluate diagnostic evolution over time, treatment responses, and prognostic factors associated with clinical outcomes.
Eligibility criteria
Qualifiers
Episodic acute vertigo, dizziness or unsteadiness transient or in evolution, therefore, lasting <24 h
focal central neurological symptoms or severe postural instability;
new-onset, moderate-to-severe craniocervical pain; or
symptoms that are not better accounted for by another disease or disorder.
Disqualifiers
Patients who present with findings of acute hemorrhage or ischemia on the cranial magnetic resonance imaging (MRI), including diffusion-weighted MRI (DWI-MRI) at recruitment;
Patients who also fulfill the diagnostic criteria for other neurotological diseases that may present acute or recurrent transient dizziness/Vertigo (Unilateral Vestibulopathy; benign paroxysmal positional vertigo; Meniére's disease; Vestibular Migraine; Vestibular Paroxysmia; Persistente Postural-Perceptual Dizziness; and Postural Hypotension;
Patients whose symptoms last more than 24 hours or who have evidence of sequelae during follow-up;
Patients with contraindications to any of the therapeutic options proposed by this study method;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
400 Participants
are grouped into 4 trial groupsSponsors and collaborators
University of Sao Paulo General Hospital
Lead sponsor
Seoul National University Bundang Hospital
Collaborator
University of Zurich
Collaborator
University College, London
Collaborator
LMU Klinikum
Collaborator
Source ClinicalTrials.gov